Advances in synthesis of pimavanserin / 国际药学研究杂志
Journal of International Pharmaceutical Research
; (6): 688-691, 2016.
Article
em Zh
| WPRIM
| ID: wpr-498132
Biblioteca responsável:
WPRO
ABSTRACT
Pimavanserin(Nuplazid) is a drug of selective targeting 5-HT2A receptor,developed by Acadia Pharmaceuticals. In April 29,2016,it was approved by FDA for the treatment of Parkinson′s disease(PD)patients experiencing mental symptoms such as hallucinations and delusions. In this paper,we summarize the synthetic methods of pimavanserin published in literature in re?cent years and their advantages and disadvantages.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of International Pharmaceutical Research
Ano de publicação:
2016
Tipo de documento:
Article